Close menu




February 14th, 2024 | 07:00 CET

Plug Power, Bayer, Defense Metals: Shares in panic mode

  • Mining
  • RareEarths
  • Hydrogen
  • Pharma
Photo credits: pixabay.com

Is everything not so bad at Plug Power, after all? In January, the hydrogen specialist triggered panic among investors with an announced capital increase. Now, the CEO is suddenly rowing back. So, should one buy the stock now? One analyst advises caution. Bayer shareholders are also in panic mode. The downward trend of the share simply cannot find a bottom. Even at this level, analysts are cautious. Defense Metals, on the other hand, is benefiting from panic - because this concerns the supply of rare earths. The dependence on China is enormous. Defense Metals aims to change this with its rare earth project in Canada. The Company CEO expressed confidence in an interview, stating that an important agreement has been reached with the local population, and important dates are on the horizon.

time to read: 4 minutes | Author: Fabian Lorenz
ISIN: PLUG POWER INC. DL-_01 | US72919P2020 , BAYER AG NA O.N. | DE000BAY0017 , DEFENSE METALS CORP. | CA2446331035

Table of contents:


    Defense Metals benefits from panic and gains important partner

    After the price jump at the end of 2023, the Defense Metals share is currently consolidating. CEO Craig Taylor points out that the share's potential is far from being fully realized. In an interview with kapitalerhöhungen.de, he highlights the panic on the market for rare earths. China has practically built up a monopoly in this area. "Western governments have woken up and recognized the risks", says Taylor. However, new projects are scarce worldwide. The Canadian company Defense Metals is developing the Wicheeda project in British Columbia, a real gem in the sector. Defense Metals has therefore submitted funding applications to the Canadian government and the US Department of Defense. According to Taylor, three defense companies also intend to assist in developing the deposit. (Click here for the interview).

    Over the past six years, around 15 km of drilling has been carried out to develop and mitigate risks. The measured and indicated resource estimate is now over 34.3 million tons. **The Company expects to produce 25,0000 tons of rare earths annually, representing around 10% of global production. The lifespan of the mine is estimated at around 20 years. Shareholders can look forward to further exciting details in the second half of 2024, when the pre-feasibility study is scheduled to be published.

    Defense Metals recently brought McLeod Lake Indian Band (MLIB) on board as an important partner on the road to development. The MLIB is an association of local indigenous people. The MLIB has invested around 2.6 million shares in Defense Metals and is also to be involved in the development of Wicheeda. This applies in particular to decisions relating to technical, social and environmental aspects. A representative of MLIB said: *"The McLeod Lake Indian Band values the partnership with Defense Metals*, and together, we are setting new standards in joint project development, which is a true form of reconciliation. We are proud to be part of a project that will make an important contribution to the goals of the global energy transition and provide long-term economic benefits to our community for generations to come."

    Plug Power: Analyst warns after share price jump

    The Plug Power share is facing a different kind of panic. Last year, the Company hinted at impending capital measures. In January 2024, a possible capital increase with a volume of around USD 1 billion was then announced, signaling a massive dilution for existing shareholders. Accordingly, the share price slumped to around USD 2.40 in mid-January. To put this in perspective, at the start of 2021, the Plug share was trading at over USD 60. However, hopes for the prospects of hydrogen technology have not materialized as expected. Hype companies such as Nel and Plug Power are growing more slowly than expected and are unable to get their high losses under control. Plug Power's liquid assets have melted from USD 690 million to around USD 110 million in the first three quarters of 2023, yet the share price has almost doubled again in recent weeks. Why? A production plant was finally put into operation in the US state of Georgia. In addition, the prospect of state debt financing was announced. Most recently, Plug CEO Andy Marsh mentioned the possibility that the capital increase could be smaller than feared. However, shareholders should take this statement with caution. In the past year alone, the Company has had to reduce its forecasts several times. The Company's communication is far from reliable. The analysts at Seaport Research also have reservations about the recent jump in the share price, downgrading their rating from "Buy" to "Hold". While Plug Power is attempting to reduce its losses and raise new capital, the risk-reward ratio at the current price level is considered fair.

    Bayer shares not a buy despite price decline

    Despite the fall in the share price below the EUR 30 mark, analysts still only see Bayer shares as a hold. In the past week, three analysts published updates on the DAX-listed company. None of the experts were able to come up with a Buy recommendation. The analysts from Jefferies and JP Morgan refer to a report from the Bloomberg news service. According to the report, a court in the US state of Arizona has stopped the Environmental Protection Agency (EPA) from approving the pesticide dicamba for the time being. A permanent ban would noticeably impact Bayer's sales and earnings development.

    Deutsche Bank has reduced its price target for Bayer shares from EUR 45 to EUR 34. Overall, there are many uncertainties. An end to the legal disputes is not in sight. The strategic direction is also unclear. The analysts consider a split-up of the Company to be unlikely.


    All three shares will remain exciting in the current year. For Defense Metals, there are compelling reasons for rising prices. The battle for rare earths has only just begun. The partnership with indigenous communities reduces the risk of legal disputes. It is likely that the share price will rise even before the pre-feasibility study is published. A tragic example of the risk of litigation is Bayer. The Company simply cannot catch a break. Yet it urgently needs capital to drive forward its drug pipeline, for example. Plug Power will also be driven by wild speculation until the capital increase is completed. Even then, the path to profitability remains long and challenging.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as shareholders, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price development. In this context, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). The Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.

    In this respect, there is a concrete conflict of interest in the reporting on the companies.

    Apaton Finance GmbH reserves the right to enter into paid contractual relationships with the company or with third parties in the future with regard to reports about the company that are reported on the Apaton Finance GmbH website as well as in social media, on partner sites or in e-mail messages.
    The above information on conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications about companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Stefan Feulner on December 10th, 2024 | 07:30 CET

    Novo Nordisk, BioNxt Solutions, Bayer – The market continues to boom

    • Biotechnology
    • Biotech
    • Pharma

    The weight-loss drug market was one of the fastest-growing sectors in the past year and shows no signs of slowing down in 2025. Companies like Novo Nordisk have seen their valuations multiply in recent years, significantly boosting their market capitalization. At the same time, smaller life sciences companies in the second tier, such as those with breakthrough technologies, offer interesting entry opportunities.

    Read

    Commented by Fabian Lorenz on December 10th, 2024 | 07:15 CET

    HIGHFLYER stocks with upside potential: Renk, TUI, Almonty Industries

    • Mining
    • Tungsten
    • Defense
    • Travel

    The current year has seen the beginning of a revaluation of Almonty Industries. The tungsten producer's stock has already gained more than 50%. If analysts have their way, it could gain another 250%. According to analysts, there could still be over 250% upside potential, as the Company is on the verge of a revenue and profit surge with the opening of a mega-mine. The TUI share has finally jumped above the EUR 8 mark. Driven by statements about a strong summer season in 2025, there is room for further growth. At its IPO, Renk was sold as a high-flyer in the defense sector. While the Company has yet to live up to these high expectations, analysts see over 50% price potential.

    Read

    Commented by André Will-Laudien on December 10th, 2024 | 07:00 CET

    Biotech Acquisitions in 2025: Several 100% Gains Expected – Evotec, Vidac Pharma, BioNTech, and Pfizer

    • Biotech
    • Pharma
    • Biotechnology

    There have already been two attempts, but the story continues! Evotec speculators were confronted with a rumor mill and a takeover bid in November. This is what happens when a stock plummets and languishes for a long time. The management wisely rejected Halozyme's undervalued offer, and thus, the bidding war for the Hamburg-based company began anew. In the biotech sector, eyes should now be on the future, as the first movements have already taken place. In our stock selection, there are three outliers with price increases of more than 30% in the last 3 months. However, the big moves will only take place in 2025. Here is an analytical look at a long-neglected sector.

    Read